Blank, Christian U.
Rozeman, Elisa A.
Fanchi, Lorenzo F.
Sikorska, Karolina
van de Wiel, Bart
Kvistborg, Pia
Krijgsman, Oscar
van den Braber, Marlous
Philips, Daisy
Broeks, Annegien
van Thienen, Johannes V.
Mallo, Henk A.
Adriaansz, Sandra
ter Meulen, Sylvia
Pronk, Loes M.
Grijpink-Ongering, Lindsay G.
Bruining, Annemarie
Gittelman, Rachel M.
Warren, Sarah
van Tinteren, Harm
Peeper, Daniel S.
Haanen, John B. A. G.
van Akkooi, Alexander C. J.
Schumacher, Ton N.
Article History
Received: 13 April 2018
Accepted: 6 August 2018
First Online: 8 October 2018
Competing interests
: C.U.B. reports personal fees for advisory roles for MSD, BMS, Roche, GSK, Novartis, Pfizer, GenMab, and Lilly, and grants from BMS, NanoString, and Novartis,outside the submitted work. E.A.R. reports travel support from NanoString Technologies and MSD, outside the submitted work. L.F.F., K.S., B.vd.W., P.K., O.K., M.vd.B., D.P., A. Broeks., H.A.M., S.A., S.t.M., L.M.P., L.G.G.-O., A. Bruining, and H.v.T. have nothing to disclose. J.V.v.T reports travel support from Roche, outside the submitted work. R.M.G. has a financial interest in Adaptive Biotechnologies. S.W. is an employee of and is a stockholder in NanoString Technologies, has an advisory role with Roche, and is a former employee of the Oncofactor Corporation, outside the submitted work. D.S.P. reports research support from BMS. J.B.A.G.H. reports that NKI received fees for his advisory roles from BMS, MSD, Roche, Neon Therapeutics, Immunocore, Novartis, AstraZeneca/MedImmune, Pfizer, and Ipsen; NKI received grants from BMS, Merck, Novartis, and Neon Therapeutics, outside the submitted work. A.C.J.v.A. reports personal fees for an advisory role with Amgen, Bristol-Myers Squibb, Novartis, MSD-Merck, and Merck-Pfizer, and grants from Amgen and Novartis, all outside the submitted work. T.N.S. is consultant for Adaptive Biotechnologies, AIMM Therapeutics, Amgen, Neon Therapeutics, Scenic Biotech, and reports grant/research support from Merck, Bristol-Myers Squibb, and Merck KGaA; he is a stockholder in AIMM Therapeutics and Neon Therapeutics.